A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

Tokyo Electric Power Company announced it has successfully completed the trial removal of a sample of fuel debris from the ...

The nuclear fuel sample, the size of a grain of rice, was placed into a secure container Thursday, marking the end of the ...

Japan is accurately monitoring occupational radiation exposure of workers involved in handling ALPS-treated water at the Fukushima Daiichi Nuclear Power Station (FDNPS), the International Atomic ...

Daiichi Jitsugyo Co., Ltd. (JP:8059) has released an update. Daiichi Jitsugyo Co., Ltd. reported robust growth in its financial results for the ...

Japanese nuclear plant workers for the first time have removed a small amount of melted fuel from one of the Fukushima ...

AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Ideaya Biosciences has decided to go ahead with its plans to grab a bispecific antibody-drug conjugate (ADC) from Biocytogen, exercising an option to pick up a preclinical asset from the Chinese ...